Alteogen enters into an Exclusive License Agreement to Develop …
3 days ago · Alteogen Inc. is a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters, and ...
Alteogen enters into an Exclusive License Agreement to Develop …
3 days ago · DAEJEON, South Korea, Nov. 10, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme™ Technology, to develop and commercialize a ...
Daiichi Sankyo partners Alteogen on subcutaneous Enhertu
6 days ago · Alteogen will receive an upfront payment of $20 million, with another $280 million on offer from Daiichi Sankyo if the new formulation of Enhertu (trastuzumab deruxtecan) makes it to market and ...
Alteogen Enters into an Exclusive License Agreement to Develop …
3 days ago · Alteogen Inc. announced that the company has entered into an exclusive license agreement with Daiichi Sankyo. Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme Technology, to develop and commercialize a subcutaneous version of ENHERTU (fam ...
Alteogen Enters License Deal With Daiichi Sankyo For ALT-B4 In ...
3 days ago · (RTTNews) - Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the deal, Daiichi Sankyo will acquire world-wide rights ...
Daiichi Sankyo links up with Korea's Alteogen on subcutaneous …
6 days ago · Under the deal, Daiichi will pay Alteogen $20 million upfront to develop the subcutaneous (SC) Enhertu formulation using its human hyaluronidase (ALT-B4) platform, according to a Korean exchange ...
Alteogen and Daiichi Sankyo sign license deal for ADC development
3 days ago · Alteogen has entered into an exclusive license agreement with Daiichi Sankyo for the development and commercialisation of a subcutaneous version of ENHERTU (fam-trastuzumab deruxtecan-nxki), an antibody drug conjugate (ADC). ALT-B4 will be used for developing the subcutaneous formulation ENHERTU. …
Alteogen enters into an Exclusive License Agreement to Develop …
3 days ago · DAEJEON, South Korea, Nov. 11, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme™ Technology, to develop and commercialize a ...
Daiichi Sankyo to license a subcutaneous version of Enhertu (fam ...
5 days ago · Under the deal, Daiichi will pay Alteogen $20 million upfront to develop the subcutaneous (SC) Enhertu formulation using its human hyaluronidase (ALT-B4) platform, according to a Korean exchange disclosure. Commercial and development milestones could add up to another $280 million for Alteogen, plus royalties tied to sales.
Alteogen jumps as it inks licence deal with Daiichi Sankyo
5 days ago · The two companies will use ALT-B4 to develop a subcutaneous version of the antibody-drug conjugate (ADC) cancer treatment Enhertu (trastuzumab deruxtecan). The news sent Alteogen’s shares up 15% to 437,000 won. The total amount of this agreement is 300 million dollars, with a contract fee of 20 million dollars.
- Some results have been removed